News & Events
2009 Press Releases
Eidogen-Sertanty Licenses TIP to the FDA
San Diego, CA (December 8, 2009) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP&trade) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).
Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. Eidogen-Sertanty will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modeling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.
"We're extremely pleased to have licensed the TIP technology to the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief Executive Officer. "We very much look forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level."
For more information, please contact:
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.